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In this contribution, an approach developed previously for mice is used for human biopsy.
In the case of patient 1, Pt detection is performed 6 days after the last oxaliplatin infusion,
while for patient 2, the biopsy was performed more than 15 days after his ﬁrst platin
infusion and several dialysis. Even for these biological samples, experiments show that
synchrotron mediated mXRF is a suitable tool to detect Pt in kidney biopsy, and thus
probably for any organ exposed to Pt. Therefore, mXRF could also be of major interest to
decipher the mechanism beyond Pt induced neurotoxicity, ototoxicity on human biopsy.
Pharmacoavailability of chemotherapies is a major concern because some treatment fail-
ures are explained by poor tumor penetration of the active molecule. mXRF could be an
elegant way to map the distribution of Pt inside cancerous cells at the micrometer scale. Pt
and Zn are only two of the numerous trace elements that mXRF can detect; heavy metal
intoxication diagnosis and the toxicity mechanism probably could also beneﬁt from this
innovative technique.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).zin).
ed by Elsevier Masson SAS.1. Introduction
Cisplatin among platin salt based chemotherapies is of
major clinical importance in the treatment of many solid
cancers [1e6]. The main toxicity that hampers cisplatin
utilisation and therefore patient survival is itsThis is an open access article under the CC BY-NC-ND license (http://
E. Esteve et al. / C. R. Chimie 19 (2016) 1586e1589 1587nephrotoxicity. Like most tubulointerstitial acute nephritis,
cisplatin induced tubulopathy lacks speciﬁc histological
signs. This is critical because patients exposed to cisplatin
are likely to accumulate several nephrotoxic drugs and to
present multiple risk factors of tubular aggression.
In the ﬁrst part of this investigation, we have demon-
strated that mXRF using synchrotron radiation can be used
to assess presence and spatial distribution of trace ele-
ments such as Pt and Zn in mice kidneys. Interestingly the
Zn redistribution pattern as well as the Pt spatial distribu-
tion seems to be dependant on the injected Pt salt. As
oxaliplatin and carboplatin are known to cause far less
tubular damages than their cisNa conjugated counterparts
we wondered whether the signal we observed could be
speciﬁc to cisplatin induced nephropathy, and whether we
could extrapolate the observations we made in the murine
model to humans.
To further investigate this hypothesis we chose to
explore two pathological kidney biopsies gathered in the
Nephrology department of Tenon’s Hospital. Both patients
presented acute renal failure attributed to acute tubular
dysfunction after platin exposure.
2. Material and methods
All samples were investigated on the DiffAbs beamline
at Synchrotron SOLEIL (France). Details regarding the ex-
periments have been extensively given in different previ-
ous publications [7e12] and also in part I of this
investigation.
Patient 1 was a 55 year old patient, his main comor-
bidities were: liver transplantation in 2005 for chronic
alcoholic steatosis and sleep apnea syndrome. In July 2011
CT4aN2cM1 epidermoid carcinoma in the postcricoïd area
was diagnosed. A treatment according to the EXTREME
protocol (Erbitux, Cisplatin, 5Flurouracil) was initiated on
04/08/2011. Acute renal failure occurred few days after the
ﬁrst infusion, the serum creatinin increased from 96 to
607 mmol/l in 6 days. His usual medications by the time of
his admission in the nephrology intensive care unit
included: salicylate, valgancyclovir, gabapentine, tacroli-
mus, calciparin and pantoprazole. There was no clinical
evidence of infection, hemodynamic constants were
normal; the renal sonogram was normal, and prerenal
etiology was ruled out. There was neither hematuria nor
leucocyturia. There was non-selective proteinuria
measured at 898 mg/mmol creatinine for only 388 mg/
mmol creatinine of albuminuria. Immunological in-
vestigations were negative. A kidney biopsy was performed
on 19/08/2014 (Supplementary data 1), 15 days after the
last cisplatin infusion. Biopsy was cortical, 15 glomeruli
were analyzable, 4 of them were sclerotic. Two glomeruli
were ischemic. There was mild mesangial expansion in the
others. Few tubular sections showed microvacuols as seen
in anti-calcineurin toxicity. Less than 5% of the tubules were
atrophic. The tubular epithelium was a bit ﬂattened. There
were almost no necrotic casts in tubules lumens. Interstitial
ﬁbrosis interested 10e15% of the parenchyma. There was
no interstitial inﬂammation. Some arterioles showed se-
vere chronic lesions. Immunoﬂuorescence for IgG, IgA, IgM,
C3, C1q, kappa, lambda was negative. This biopsy showedonly mild tubular injuries regarding the severity of the
renal failure. The retained diagnosis was acute renal failure
secondary to cisplatin nephrotoxicity. Evolution was pejo-
rative; hemodialysis was initiated on 30/08/2014 and was
not disrupted until the patient’s death four months later.
Patient 2 was 57 at the time of the biopsy in 2011. He
was diagnosed with T4N2M1 colon liberkhunian adeno-
carcinoma in January 2008. He was treated surgically and
received multiple chemotherapies including: FOLFOX
(folinic acid, oxaliplatin and 5Fluorouracil), FOLFIRI (Folinic
Acid, 5Fluorouracile, Irinotecan), bevacizumab and capeci-
tabin. In July 2011, Folfox (including 85 mg/m2 oxalipatin)
and bevacizumab were reinitiated. On 16/9/11, during the
4th cure of FOLFOX, the patient presented shivering asso-
ciated with hyperthermia and nausea. An empiric anti-
biotherapy including tazocillin and vancomycin was initi-
ated. Subsequently, he presented acute renal failure (serum
creatinin raised from 90 mmol/l to 325 mmol/l and
804 mmol/l) with severe hyperkaliemia (6.6 mmol/l). The
patient was transferred to the intensive care unit and
extrarenal epuration had to be initiated. The renal sono-
gram was considered normal, and the blood and urinary
ionogram couldn’t distinguish prerenal participation. Blood
cell count in urine was negative, but there were hemoglo-
binuria and 3þ proteinuria on the urine dipstick. Clinically
the patient presented rapidly progressing oligoanuria. The
practician noticed acute hemolysis, thrombopenia and
coagulation factor consumption. No schizocytes were
noticed. Hyperthermia resolved within 24 h; microbiolog-
ical investigations were negative and anti-biotherapy was
disrupted. The Coombs test was 3þ positive for IgG and C3.
A kidney biopsy was performed on September 22
(Supplementary data 2). Twenty-one glomeruli were
analyzable on this cortico-medullar biopsy. Four glomeruli
were sclerotic, two were ischemic, whereas the others
didn’t show any sign of pathology. There was evidence of
acute tubular injury with many necrotic debris in tubules
lumen. Some of those debris showed a macrophagic
inﬂammation response. There were mild non-speciﬁc
interstitial inﬂammations. They were neither acute
vascular injuries nor sign of acute microangiopathy.
Immunoﬂuorescence was negative for IgA, IgG, IgM, C3,
C1q, ﬁbrin, Kappa and Lambda. The ﬁnal diagnosis was
acute tubular necrosis secondary to oxaliplatin mediated
hemolysis. Evolution was favorable and dialysis was dis-
rupted on October 3rd.Renal function slowly normalized.
Oxaliplatin was not readministrated, and the patient died
from generalized cancer on October 1, 2012.
Although these two patients both required dialysis
initially due to acute tubular injury few days after platin
salt exposure, the mechanism underneath these acute
kidney injuries is very different. As far as we can say,
cisplatin exerted direct toxicity toward the tubular cells of
patient 1, leading to their deﬁnitive destruction and to end
stage renal failure. Patient 2 suffered acute intravascular
hemolysis due to an immunoallergic mechanism. Renal
failure is secondary to the haemoglobin precipitation in the
tubules. Thereforewewonderedwhether we could identify
the presence of Pt in these two kidney biopsies and
whether it’s spatial distribution (among with Zn’s one)
would be different.
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As described in Part 1 of this project concerning an
animal model of platin induced nephritis, mXRF spectra
were acquired in large areas of the two studied biopsy with
micrometer scale resolution. They were digitally processed
to isolate ZnKa and PtLa [13]. The intensity of the respective
peaks was then used to generate maps representing spatial
distribution of these elements in the two biopsies.
The striking result of this investigation comes from the
fact that we were able to point out the presence of Pt in the
human biopsy. To the best of our knowledge, this is the ﬁrst
time that suchmeasurements were performed. Note that in
the case of patient 1(Fig.1aeb), Pt detectionwas performed
6 days after the last oxaliplatin infusion while for patient 2,
the biopsy was performed more than 15 days after his ﬁrst
oxaliplatin infusion, and several dialysis. We were also able
to detect Zn in the two patients’ biopsies (Fig. 1ced).
Pt and Zn seemed to be equally distributed in the biopsy
of patient 1. Pt and Zn seemed to be concentrated in the
medulla of patient 2. In our experience in mice, Pt and ZnFig. 1. Zn and Pt XRF maps collected for patient 1 (a and b) and for pare found in the cortex after cisplatin infusion only, and we
believe that this is somehow related to cisplatin induced
tubulopathy. This observation likely explains the asym-
metry observed in the patient 2 sample. Unfortunately in
absence of analyzable medulla in patient 1 tissue, we
cannot deﬁnitely conﬁrm our hypothesis.
Following the approach deﬁned for mice in part I of this
study, the ﬂuorescencemaps for the different samples were
analyzed using Intensity Correlation Analysis (ICA)
methods [14,15] in order to highlight possible spatial cor-
relations between Zn and Pt (Fig. 2). Although this proves
the feasibility of this measurement, the absence of medulla
in the patient 1 biopsy is clearly a limitation of such an
approach.
4. Discussion
For the ﬁrst time to the best of our knowledge, we have
shown that mXRF can detect Pt and Zn at amicrometer scale
nondestructively in human kidney biopsy. From a clinical
point of view, routine renal anatomopathology is quiteatient 2 (c and d). Cortico medullar junction is shown in black.
Fig. 2. Pearson correlation coefﬁcients between Zn and Pt obtained through
statistical analysis for the patients 1 and 2.
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acute tubular necrosis. mXRF allowed us to physically detect
the potential nephrotoxic agent in the tissue of interest.
Although the tubular lesions of patient 1 were very discrete
after standard staining, which contrasted with the severity
of the renal failure, mXRF could identify traces of remanent
Pt in the cortex. Such measurements may thus be of pri-
mary importance for the clinician.
Moreover, the spatial correlation between Pt and Zn
may also be discussed using such an approach.Whether the
zinc we measured is linked to zinc renal metabolism
modiﬁcation, protective mechanisms such as heavy metal
detoxiﬁcation metallothionein induction, a witness of
platin induced damaged DNA linked protein recruitment
such as ZNF143 or to deleterious mechanisms such as
activation and accumulation of proﬁbrotic metal-
loproteases such as MeprinA is unclear. However, cisplatin
seems to be the only Pt salt able to induce a redistribution
of renal Zn to the cortex, and this is probably an interesting
new pathway to explore.
We are aware that this study is preliminary and contains
several limitations. Renal biopsies grant access to a very
small sample of kidney tissue and the representativity of
the sample is a constant concern. Nevertheless, an advan-
tage of such an approach is that we are able to investigatethe parafﬁn bloc through a non-destructive technique.
Therefore it does not prohibit further exploitation of the
sample by the anatomopathologist. In this experiment the
lack of medullar tissue in the patient 1 biopsy hampers
greatly our ability to reproduce the cisplatin speciﬁc Pt and
Zn spatial distribution pattern we identiﬁed in mice.
Nevertheless, we believe that the unique ability of mXRF to
dissect matter could be of great utility in the understanding
and diagnosis, and therefore the prevention of Pt related
nephrotoxicity.
5. Conclusion
This set of experiments shows that synchrotron medi-
ated mXRF is a suitable tool to detect Pt in kidney biopsy and
consequently probably so on any organ exposed to Pt.
Therefore, mXRF could also be of major interest to decipher
the mechanism beyond Pt induced neurotoxicity, ototox-
icity. Pharmacoavailability of chemotherapies is a major
concern because some treatment failures are explained by
poor tumor penetration of the active molecule. Thus mXRF
could be an elegant way to map the distribution of Pt inside
cancerous cells at the micrometer scale. Pt and Zn are only
two of the numerous trace elements mXRF can detect.
Heavy metal intoxication, diagnosis and toxicity mecha-
nisms could probably also beneﬁt from this innovative
technique.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at http://dx.doi.org/10.1016/j.crci.2016.02.015.References
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